Merck: teams up with CEPI to make the Ebola vaccine more accessible in low-income countries

Merck has partnered with CEPI to enhance the accessibility of its Ebola vaccine, Ervebo, in low-income countries. The $30 million initiative aims to improve manufacturing and distribution, increasing vaccine yield and shelf life. Collaborating with Hilleman Laboratories, the project will also consider differentiated pricing for public-sector buyers. Key improvements include enabling storage in standard refrigerators, facilitating distribution in remote areas. This partnership is part of a global effort to make epidemic vaccines more sustainable and strengthen outbreak response in vulnerable regions.